The Experts below are selected from a list of 14685 Experts worldwide ranked by ideXlab platform
Brian J. Reid - One of the best experts on this subject based on the ideXlab platform.
-
optimizing Endoscopic Biopsy detection of early cancers in barrett s high grade dysplasia
The American Journal of Gastroenterology, 2000Co-Authors: Patricia L. Blount, Brian J. Reid, Ziding Feng, Douglas S. LevineAbstract:OBJECTIVE: The management of high-grade dysplasia (HGD) in Barrett’s esophagus remains controversial, in part, because of uncertainty about the ability of Endoscopic biopsies to consistently detect early, curable cancers. METHODS: Here we report cancers we have diagnosed in 45 patients with Barrett’s HGD using a protocol involving serial endoscopies with four-quadrant biopsies taken at 1-cm intervals. We compare these results to a modeled Endoscopic Biopsy protocol in which four-quadrant biopsies are taken every 2 cm in the Barrett’s segment. RESULTS: Thirteen cancers were detected at the baseline endoscopy and 32 in surveillance. In 82% of patients, cancer was detected at a single 1-cm level of the esophagus, and in 69% the cancer was detected in a single Endoscopic Biopsy specimen. A 2-cm protocol missed 50% of cancers that were detected by a 1-cm protocol in Barrett’s segments 2 cm or more without visible lesions. The maximum depth of cancer invasion was intramucosal in 96% of patients. Only 39% of patients who had Endoscopic Biopsy cancer diagnoses had cancer detected in the esophagectomy specimen. Adverse outcomes included the development of regional metastatic disease during surveillance (1 of 32), operative mortality (3 of 36), including two patients who had their primary surgeries at other institutions, and death from metastatic disease after Endoscopic ablation performed at another institution (1 of 3). CONCLUSIONS: A four-quadrant, 1-cm Endoscopic Biopsy protocol performed at closely timed intervals consistently detects early cancers arising in HGD in Barrett’s esophagus and should be used in patients with HGD who do not undergo surgical resection.
-
predictors of progression to cancer in barrett s esophagus baseline histology and flow cytometry identify low and high risk patient subsets
The American Journal of Gastroenterology, 2000Co-Authors: Brian J. Reid, Patricia L. Blount, Douglas S. Levine, Gary Longton, Peter S. RabinovitchAbstract:Abstract OBJECTIVE: Barrett’s esophagus develops in 5–20% of patients with gastroesophageal reflux disease and predisposes to esophageal adenocarcinoma. The value of Endoscopic Biopsy surveillance is questioned because most patients do not develop cancer. Furthermore, observer variation in histological diagnosis makes validation of surveillance guidelines difficult because varying histological interpretations may lead to different estimated rates of progression. Thus, objective biomarkers need to be validated for use with histology to stratify patients according to their risk for progression to cancer. METHODS: We prospectively evaluated patients using a systematic Endoscopic Biopsy protocol with baseline histological and flow cytometric abnormalities as predictors and cancer as the outcome. RESULTS: Among patients with negative, indefinite, or low-grade dysplasia, those with neither aneuploidy nor increased 4N fractions had a 0% 5-yr cumulative cancer incidence compared with 28% for those with either aneuploidy or increased 4N. Patients with baseline increased 4N, aneuploidy, and high-grade dysplasia had 5-yr cancer incidences of 56%, 43%, and 59%, respectively. Aneuploidy, increased 4N, or HGD were detected at baseline in all 35 patients who developed cancer within 5 yr. CONCLUSIONS: A systematic baseline Endoscopic Biopsy protocol using histology and flow cytometry identifies subsets of patients with Barrett’s esophagus at low and high risk for progression to cancer. Patients whose baseline biopsies are negative, indefinite, or low-grade displasia without increased 4N or aneuploidy may have surveillance deferred for up to 5 yr. Patients with cytometric abnormalities merit more frequent surveillance, and management of high-grade displasia can be individualized.
-
safety of a systematic Endoscopic Biopsy protocol in patients with barrett s esophagus
The American Journal of Gastroenterology, 2000Co-Authors: Douglas S. Levine, Patricia L. Blount, Rebecca E Rudolph, Brian J. ReidAbstract:Abstract OBJECTIVE: Widespread implementation of rigorous, systematic Endoscopic Biopsy protocols for patients with Barrett’s esophagus may be hindered by concerns about their safety. This report describes the safety experience of a large series of patients with gastroesophageal reflux disease and Barrett’s esophagus who underwent such procedures. METHODS: Patients in the Seattle Barrett’s Esophagus Project undergo Biopsy surveillance in a research-based clinical setting, using large channel endoscopes and “jumbo” Biopsy forceps. After visual inspection, multiple biopsies are obtained from lesions and at 1- to 2-cm intervals throughout the Barrett’s esophageal segment. RESULTS: From 1983 to 1997, 1,458 consecutive endoscopies were performed on 705 patients and 50,833 biopsies (average, 35; maximum, 120 per procedure) were taken. Procedures lasted from 15 to 90 min during which one to two biopsies were obtained per minute. Eleven patients experienced 18 significant adverse events, five of which led to overnight hospitalizations: two for bleeding attributed to concomitant esophageal stricture dilation; two for cardiac dysrhythmias; and one for respiratory arrest. Events managed in outpatient settings included chest pain during seven endoscopies (all accounted for by two patients), chest or epigastric pain developing after five endoscopies, and one tonsillar abrasion. All patients recovered completely, and no deaths, perforations, aspiration, or esophageal stricturing resulted from the procedures. CONCLUSIONS: A rigorous, systematic Endoscopic Biopsy protocol in patients with Barrett’s esophagus does not produce esophageal perforation or bleeding when performed by an experienced team of physicians, nurses, and technicians.
-
An Endoscopic Biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus
Gastroenterology, 1993Co-Authors: Douglas S. Levine, R. C. Haggitt, Patricia L. Blount, Peter S. Rabinovitch, Valerie W. Rusch, Brian J. ReidAbstract:Abstract Background: Surveying vs. performing resection in patients with high-grade dysplasia in Barrett's esophagus is debated because of concern about the accuracy of Endoscopic Biopsy diagnosis. The aim of this study was to investigate the accuracy of an Endoscopic Biopsy protocol in patients with neoplastic abnormalities in Barrett's epithelium without obvious esophageal cancer. Methods: Preoperative and postoperative diagnoses in 28 patients who underwent surgery for high-grade dysplasia or early adenocarcinoma in Barrett's esophagus and compared them with 22 other patients with high-grade dysplasia who were maintained under prospective Endoscopic surveillance. All 50 patients lacked gross lesions to suggest esophageal cancer. The Endoscopic protocol involved rigorous, systematic acquisition of multiple, large Biopsy samples. Results: Overall, 64% of patients had minimal but distinct Endoscopic abnormalities that were targeted for biopsies. High-grade dysplasia alone (7 patients) was differentiated from early adenocarcinoma (19 patients). Two patients with preoperative diagnoses of intramucosal adenocarcinoma had high-grade dysplasia in their resection specimens. Conclusions: This Endoscopic protocol accurately detects and differentiates high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Patients with high-grade dysplasia alone in Barrett's esophagus detected by such a protocol do not necessarily require surgical resection to rule out an undiagnosed adenocarcinoma; electing for surgery should be based on other clinical considerations.
Hiroyuki Okada - One of the best experts on this subject based on the ideXlab platform.
-
technique for single step lymphocyte isolation from an Endoscopic Biopsy specimen for the diagnosis of gastrointestinal lymphoma
MethodsX, 2020Co-Authors: Masaya Iwamuro, Takahide Takahashi, Natsuki Watanabe, Sizuma Omote, Katsunori Matsueda, Takehiro Tanaka, Daisuke Ennishi, Fumio Otsuka, Tadashi Yoshino, Hiroyuki OkadaAbstract:ABSTRACT In this paper, we introduce a simplified, one-step procedure for lymphocyte isolation from an Endoscopically biopsied fragment. For lymphocyte isolation, an Endoscopically harvested specimen and 5 mL of normal saline solution were placed in a wire mesh strainer set in a porcelain bowl. To obtain the lymphocyte suspension, the solid specimen was crushed using the rubber portion of a plunger of a 10 mL injection syringe. Flow cytometry was performed using the lymphocyte suspension. For validating our methods, the one-step lymphocyte isolation technique was used to perform flow cytometry on samples from 23 patients with (n = 12) or without (n = 11) gastrointestinal lymphoma. Flow cytometry of light chain expression was performed in all patient samples (feasibility: 100%). Sensitivity was 83.3% (10/12) and specificity was 100% (11/11). In conclusion, lymphocytes isolated from a single Endoscopic Biopsy specimen using our simplified and quick procedure are suitable for flow cytometry. Considering that flow cytometry has an important advantage of providing the results on the examination day itself, the results of this study suggest that flow cytometric analysis using our single-step lymphocyte isolation technique can be potentially used to diagnose lymphoma in the gastrointestinal mucosa. Bullet points We introduce a simplified, one-step procedure for lymphocyte isolation from an Endoscopically biopsied fragment. Our technique is feasible for flow cytometric analysis in patients with gastrointestinal lymphoma as well as those with gastrointestinal lesions that are suspected to be lymphoma.
-
feasibility of flow cytometric analysis of restricted light chain in Endoscopic Biopsy specimens from patients with gastrointestinal tract b cell lymphoma a pilot study
BMC Research Notes, 2019Co-Authors: Katsunori Matsueda, Masaya Iwamuro, Takahide Takahashi, Sizuma Omote, Takehiro Tanaka, Daisuke Ennishi, Fumio Otsuka, Tadashi Yoshino, Kenji Nishida, Hiroyuki OkadaAbstract:Objective Gastrointestinal tract lymphomas are currently detected more frequently due to advances in Endoscopic technology. The aim of this study was to assess the feasibility of flow cytometric analysis of restricted light chain in Endoscopic Biopsy specimens for the diagnosis of gastrointestinal tract B-cell lymphoma. We prepared viable cell suspensions from unfixed specimens obtained from 10 consecutive patients who had a previous histological diagnosis of gastrointestinal tract B-cell lymphoma. We performed immunophenotypic studies with multi-color flow cytometry and assessed clonality through examination of immunoglobulin light chain expression exclusively in a population identified by anti-CD45 or CD20 antibodies.
Douglas S. Levine - One of the best experts on this subject based on the ideXlab platform.
-
optimizing Endoscopic Biopsy detection of early cancers in barrett s high grade dysplasia
The American Journal of Gastroenterology, 2000Co-Authors: Patricia L. Blount, Brian J. Reid, Ziding Feng, Douglas S. LevineAbstract:OBJECTIVE: The management of high-grade dysplasia (HGD) in Barrett’s esophagus remains controversial, in part, because of uncertainty about the ability of Endoscopic biopsies to consistently detect early, curable cancers. METHODS: Here we report cancers we have diagnosed in 45 patients with Barrett’s HGD using a protocol involving serial endoscopies with four-quadrant biopsies taken at 1-cm intervals. We compare these results to a modeled Endoscopic Biopsy protocol in which four-quadrant biopsies are taken every 2 cm in the Barrett’s segment. RESULTS: Thirteen cancers were detected at the baseline endoscopy and 32 in surveillance. In 82% of patients, cancer was detected at a single 1-cm level of the esophagus, and in 69% the cancer was detected in a single Endoscopic Biopsy specimen. A 2-cm protocol missed 50% of cancers that were detected by a 1-cm protocol in Barrett’s segments 2 cm or more without visible lesions. The maximum depth of cancer invasion was intramucosal in 96% of patients. Only 39% of patients who had Endoscopic Biopsy cancer diagnoses had cancer detected in the esophagectomy specimen. Adverse outcomes included the development of regional metastatic disease during surveillance (1 of 32), operative mortality (3 of 36), including two patients who had their primary surgeries at other institutions, and death from metastatic disease after Endoscopic ablation performed at another institution (1 of 3). CONCLUSIONS: A four-quadrant, 1-cm Endoscopic Biopsy protocol performed at closely timed intervals consistently detects early cancers arising in HGD in Barrett’s esophagus and should be used in patients with HGD who do not undergo surgical resection.
-
predictors of progression to cancer in barrett s esophagus baseline histology and flow cytometry identify low and high risk patient subsets
The American Journal of Gastroenterology, 2000Co-Authors: Brian J. Reid, Patricia L. Blount, Douglas S. Levine, Gary Longton, Peter S. RabinovitchAbstract:Abstract OBJECTIVE: Barrett’s esophagus develops in 5–20% of patients with gastroesophageal reflux disease and predisposes to esophageal adenocarcinoma. The value of Endoscopic Biopsy surveillance is questioned because most patients do not develop cancer. Furthermore, observer variation in histological diagnosis makes validation of surveillance guidelines difficult because varying histological interpretations may lead to different estimated rates of progression. Thus, objective biomarkers need to be validated for use with histology to stratify patients according to their risk for progression to cancer. METHODS: We prospectively evaluated patients using a systematic Endoscopic Biopsy protocol with baseline histological and flow cytometric abnormalities as predictors and cancer as the outcome. RESULTS: Among patients with negative, indefinite, or low-grade dysplasia, those with neither aneuploidy nor increased 4N fractions had a 0% 5-yr cumulative cancer incidence compared with 28% for those with either aneuploidy or increased 4N. Patients with baseline increased 4N, aneuploidy, and high-grade dysplasia had 5-yr cancer incidences of 56%, 43%, and 59%, respectively. Aneuploidy, increased 4N, or HGD were detected at baseline in all 35 patients who developed cancer within 5 yr. CONCLUSIONS: A systematic baseline Endoscopic Biopsy protocol using histology and flow cytometry identifies subsets of patients with Barrett’s esophagus at low and high risk for progression to cancer. Patients whose baseline biopsies are negative, indefinite, or low-grade displasia without increased 4N or aneuploidy may have surveillance deferred for up to 5 yr. Patients with cytometric abnormalities merit more frequent surveillance, and management of high-grade displasia can be individualized.
-
safety of a systematic Endoscopic Biopsy protocol in patients with barrett s esophagus
The American Journal of Gastroenterology, 2000Co-Authors: Douglas S. Levine, Patricia L. Blount, Rebecca E Rudolph, Brian J. ReidAbstract:Abstract OBJECTIVE: Widespread implementation of rigorous, systematic Endoscopic Biopsy protocols for patients with Barrett’s esophagus may be hindered by concerns about their safety. This report describes the safety experience of a large series of patients with gastroesophageal reflux disease and Barrett’s esophagus who underwent such procedures. METHODS: Patients in the Seattle Barrett’s Esophagus Project undergo Biopsy surveillance in a research-based clinical setting, using large channel endoscopes and “jumbo” Biopsy forceps. After visual inspection, multiple biopsies are obtained from lesions and at 1- to 2-cm intervals throughout the Barrett’s esophageal segment. RESULTS: From 1983 to 1997, 1,458 consecutive endoscopies were performed on 705 patients and 50,833 biopsies (average, 35; maximum, 120 per procedure) were taken. Procedures lasted from 15 to 90 min during which one to two biopsies were obtained per minute. Eleven patients experienced 18 significant adverse events, five of which led to overnight hospitalizations: two for bleeding attributed to concomitant esophageal stricture dilation; two for cardiac dysrhythmias; and one for respiratory arrest. Events managed in outpatient settings included chest pain during seven endoscopies (all accounted for by two patients), chest or epigastric pain developing after five endoscopies, and one tonsillar abrasion. All patients recovered completely, and no deaths, perforations, aspiration, or esophageal stricturing resulted from the procedures. CONCLUSIONS: A rigorous, systematic Endoscopic Biopsy protocol in patients with Barrett’s esophagus does not produce esophageal perforation or bleeding when performed by an experienced team of physicians, nurses, and technicians.
-
An Endoscopic Biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus
Gastroenterology, 1993Co-Authors: Douglas S. Levine, R. C. Haggitt, Patricia L. Blount, Peter S. Rabinovitch, Valerie W. Rusch, Brian J. ReidAbstract:Abstract Background: Surveying vs. performing resection in patients with high-grade dysplasia in Barrett's esophagus is debated because of concern about the accuracy of Endoscopic Biopsy diagnosis. The aim of this study was to investigate the accuracy of an Endoscopic Biopsy protocol in patients with neoplastic abnormalities in Barrett's epithelium without obvious esophageal cancer. Methods: Preoperative and postoperative diagnoses in 28 patients who underwent surgery for high-grade dysplasia or early adenocarcinoma in Barrett's esophagus and compared them with 22 other patients with high-grade dysplasia who were maintained under prospective Endoscopic surveillance. All 50 patients lacked gross lesions to suggest esophageal cancer. The Endoscopic protocol involved rigorous, systematic acquisition of multiple, large Biopsy samples. Results: Overall, 64% of patients had minimal but distinct Endoscopic abnormalities that were targeted for biopsies. High-grade dysplasia alone (7 patients) was differentiated from early adenocarcinoma (19 patients). Two patients with preoperative diagnoses of intramucosal adenocarcinoma had high-grade dysplasia in their resection specimens. Conclusions: This Endoscopic protocol accurately detects and differentiates high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Patients with high-grade dysplasia alone in Barrett's esophagus detected by such a protocol do not necessarily require surgical resection to rule out an undiagnosed adenocarcinoma; electing for surgery should be based on other clinical considerations.
Patricia L. Blount - One of the best experts on this subject based on the ideXlab platform.
-
optimizing Endoscopic Biopsy detection of early cancers in barrett s high grade dysplasia
The American Journal of Gastroenterology, 2000Co-Authors: Patricia L. Blount, Brian J. Reid, Ziding Feng, Douglas S. LevineAbstract:OBJECTIVE: The management of high-grade dysplasia (HGD) in Barrett’s esophagus remains controversial, in part, because of uncertainty about the ability of Endoscopic biopsies to consistently detect early, curable cancers. METHODS: Here we report cancers we have diagnosed in 45 patients with Barrett’s HGD using a protocol involving serial endoscopies with four-quadrant biopsies taken at 1-cm intervals. We compare these results to a modeled Endoscopic Biopsy protocol in which four-quadrant biopsies are taken every 2 cm in the Barrett’s segment. RESULTS: Thirteen cancers were detected at the baseline endoscopy and 32 in surveillance. In 82% of patients, cancer was detected at a single 1-cm level of the esophagus, and in 69% the cancer was detected in a single Endoscopic Biopsy specimen. A 2-cm protocol missed 50% of cancers that were detected by a 1-cm protocol in Barrett’s segments 2 cm or more without visible lesions. The maximum depth of cancer invasion was intramucosal in 96% of patients. Only 39% of patients who had Endoscopic Biopsy cancer diagnoses had cancer detected in the esophagectomy specimen. Adverse outcomes included the development of regional metastatic disease during surveillance (1 of 32), operative mortality (3 of 36), including two patients who had their primary surgeries at other institutions, and death from metastatic disease after Endoscopic ablation performed at another institution (1 of 3). CONCLUSIONS: A four-quadrant, 1-cm Endoscopic Biopsy protocol performed at closely timed intervals consistently detects early cancers arising in HGD in Barrett’s esophagus and should be used in patients with HGD who do not undergo surgical resection.
-
predictors of progression to cancer in barrett s esophagus baseline histology and flow cytometry identify low and high risk patient subsets
The American Journal of Gastroenterology, 2000Co-Authors: Brian J. Reid, Patricia L. Blount, Douglas S. Levine, Gary Longton, Peter S. RabinovitchAbstract:Abstract OBJECTIVE: Barrett’s esophagus develops in 5–20% of patients with gastroesophageal reflux disease and predisposes to esophageal adenocarcinoma. The value of Endoscopic Biopsy surveillance is questioned because most patients do not develop cancer. Furthermore, observer variation in histological diagnosis makes validation of surveillance guidelines difficult because varying histological interpretations may lead to different estimated rates of progression. Thus, objective biomarkers need to be validated for use with histology to stratify patients according to their risk for progression to cancer. METHODS: We prospectively evaluated patients using a systematic Endoscopic Biopsy protocol with baseline histological and flow cytometric abnormalities as predictors and cancer as the outcome. RESULTS: Among patients with negative, indefinite, or low-grade dysplasia, those with neither aneuploidy nor increased 4N fractions had a 0% 5-yr cumulative cancer incidence compared with 28% for those with either aneuploidy or increased 4N. Patients with baseline increased 4N, aneuploidy, and high-grade dysplasia had 5-yr cancer incidences of 56%, 43%, and 59%, respectively. Aneuploidy, increased 4N, or HGD were detected at baseline in all 35 patients who developed cancer within 5 yr. CONCLUSIONS: A systematic baseline Endoscopic Biopsy protocol using histology and flow cytometry identifies subsets of patients with Barrett’s esophagus at low and high risk for progression to cancer. Patients whose baseline biopsies are negative, indefinite, or low-grade displasia without increased 4N or aneuploidy may have surveillance deferred for up to 5 yr. Patients with cytometric abnormalities merit more frequent surveillance, and management of high-grade displasia can be individualized.
-
safety of a systematic Endoscopic Biopsy protocol in patients with barrett s esophagus
The American Journal of Gastroenterology, 2000Co-Authors: Douglas S. Levine, Patricia L. Blount, Rebecca E Rudolph, Brian J. ReidAbstract:Abstract OBJECTIVE: Widespread implementation of rigorous, systematic Endoscopic Biopsy protocols for patients with Barrett’s esophagus may be hindered by concerns about their safety. This report describes the safety experience of a large series of patients with gastroesophageal reflux disease and Barrett’s esophagus who underwent such procedures. METHODS: Patients in the Seattle Barrett’s Esophagus Project undergo Biopsy surveillance in a research-based clinical setting, using large channel endoscopes and “jumbo” Biopsy forceps. After visual inspection, multiple biopsies are obtained from lesions and at 1- to 2-cm intervals throughout the Barrett’s esophageal segment. RESULTS: From 1983 to 1997, 1,458 consecutive endoscopies were performed on 705 patients and 50,833 biopsies (average, 35; maximum, 120 per procedure) were taken. Procedures lasted from 15 to 90 min during which one to two biopsies were obtained per minute. Eleven patients experienced 18 significant adverse events, five of which led to overnight hospitalizations: two for bleeding attributed to concomitant esophageal stricture dilation; two for cardiac dysrhythmias; and one for respiratory arrest. Events managed in outpatient settings included chest pain during seven endoscopies (all accounted for by two patients), chest or epigastric pain developing after five endoscopies, and one tonsillar abrasion. All patients recovered completely, and no deaths, perforations, aspiration, or esophageal stricturing resulted from the procedures. CONCLUSIONS: A rigorous, systematic Endoscopic Biopsy protocol in patients with Barrett’s esophagus does not produce esophageal perforation or bleeding when performed by an experienced team of physicians, nurses, and technicians.
-
An Endoscopic Biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett's esophagus
Gastroenterology, 1993Co-Authors: Douglas S. Levine, R. C. Haggitt, Patricia L. Blount, Peter S. Rabinovitch, Valerie W. Rusch, Brian J. ReidAbstract:Abstract Background: Surveying vs. performing resection in patients with high-grade dysplasia in Barrett's esophagus is debated because of concern about the accuracy of Endoscopic Biopsy diagnosis. The aim of this study was to investigate the accuracy of an Endoscopic Biopsy protocol in patients with neoplastic abnormalities in Barrett's epithelium without obvious esophageal cancer. Methods: Preoperative and postoperative diagnoses in 28 patients who underwent surgery for high-grade dysplasia or early adenocarcinoma in Barrett's esophagus and compared them with 22 other patients with high-grade dysplasia who were maintained under prospective Endoscopic surveillance. All 50 patients lacked gross lesions to suggest esophageal cancer. The Endoscopic protocol involved rigorous, systematic acquisition of multiple, large Biopsy samples. Results: Overall, 64% of patients had minimal but distinct Endoscopic abnormalities that were targeted for biopsies. High-grade dysplasia alone (7 patients) was differentiated from early adenocarcinoma (19 patients). Two patients with preoperative diagnoses of intramucosal adenocarcinoma had high-grade dysplasia in their resection specimens. Conclusions: This Endoscopic protocol accurately detects and differentiates high-grade dysplasia from early adenocarcinoma in Barrett's esophagus. Patients with high-grade dysplasia alone in Barrett's esophagus detected by such a protocol do not necessarily require surgical resection to rule out an undiagnosed adenocarcinoma; electing for surgery should be based on other clinical considerations.
Masaya Iwamuro - One of the best experts on this subject based on the ideXlab platform.
-
technique for single step lymphocyte isolation from an Endoscopic Biopsy specimen for the diagnosis of gastrointestinal lymphoma
MethodsX, 2020Co-Authors: Masaya Iwamuro, Takahide Takahashi, Natsuki Watanabe, Sizuma Omote, Katsunori Matsueda, Takehiro Tanaka, Daisuke Ennishi, Fumio Otsuka, Tadashi Yoshino, Hiroyuki OkadaAbstract:ABSTRACT In this paper, we introduce a simplified, one-step procedure for lymphocyte isolation from an Endoscopically biopsied fragment. For lymphocyte isolation, an Endoscopically harvested specimen and 5 mL of normal saline solution were placed in a wire mesh strainer set in a porcelain bowl. To obtain the lymphocyte suspension, the solid specimen was crushed using the rubber portion of a plunger of a 10 mL injection syringe. Flow cytometry was performed using the lymphocyte suspension. For validating our methods, the one-step lymphocyte isolation technique was used to perform flow cytometry on samples from 23 patients with (n = 12) or without (n = 11) gastrointestinal lymphoma. Flow cytometry of light chain expression was performed in all patient samples (feasibility: 100%). Sensitivity was 83.3% (10/12) and specificity was 100% (11/11). In conclusion, lymphocytes isolated from a single Endoscopic Biopsy specimen using our simplified and quick procedure are suitable for flow cytometry. Considering that flow cytometry has an important advantage of providing the results on the examination day itself, the results of this study suggest that flow cytometric analysis using our single-step lymphocyte isolation technique can be potentially used to diagnose lymphoma in the gastrointestinal mucosa. Bullet points We introduce a simplified, one-step procedure for lymphocyte isolation from an Endoscopically biopsied fragment. Our technique is feasible for flow cytometric analysis in patients with gastrointestinal lymphoma as well as those with gastrointestinal lesions that are suspected to be lymphoma.
-
feasibility of flow cytometric analysis of restricted light chain in Endoscopic Biopsy specimens from patients with gastrointestinal tract b cell lymphoma a pilot study
BMC Research Notes, 2019Co-Authors: Katsunori Matsueda, Masaya Iwamuro, Takahide Takahashi, Sizuma Omote, Takehiro Tanaka, Daisuke Ennishi, Fumio Otsuka, Tadashi Yoshino, Kenji Nishida, Hiroyuki OkadaAbstract:Objective Gastrointestinal tract lymphomas are currently detected more frequently due to advances in Endoscopic technology. The aim of this study was to assess the feasibility of flow cytometric analysis of restricted light chain in Endoscopic Biopsy specimens for the diagnosis of gastrointestinal tract B-cell lymphoma. We prepared viable cell suspensions from unfixed specimens obtained from 10 consecutive patients who had a previous histological diagnosis of gastrointestinal tract B-cell lymphoma. We performed immunophenotypic studies with multi-color flow cytometry and assessed clonality through examination of immunoglobulin light chain expression exclusively in a population identified by anti-CD45 or CD20 antibodies.